WT1 and graft versus host disease: In order to promote graft-versus-leukemia (GVL) reactivity after HLA-matched allogeneic stem cell transplantation, Chapuis et al. isolated WT-1 TCR (TCRC4) from HLA-A2+ normal donor repertoires (WT-1 TCR CAR T cells) following allogeneic hematopoietic stem cell transplantation (allo-HSCT), inserted TCRC4 into Epstein–Barr virus-specific donor CD8+ T cells to minimize graft-versus-host disease and infused them prophylactically post-allo-HSCT.